Search

everythinglearnresearchcommunity

for

Search:↓

Kintor's 1% Pyrilutamide will be released in October/November. The user cannot tolerate finasteride.

The conversation is about a user's hair loss treatment regimen, which includes Dutasteride, oral Minoxidil, topical Dutasteride, Minoxidil sulfate, antioxidants, and various supplements. The user is also using a derma stamp and has paused Tretinoin due to a TCA peel recovery.

The conversation discusses switching from RU58841 to pyrilutamide for hair loss treatment, with users generally recommending staying on RU58841 if it is effective. RU58841 is sourced from GeneTherica, which ships worldwide.

Liposomal formulations of finasteride and minoxidil may enhance drug delivery to the skin and hair follicles more effectively than traditional solutions, potentially improving treatment outcomes. However, more human clinical trials are needed to confirm these benefits.

The user is using RU58841, Revivogen, Regenepure ketoconazole shampoo, and plans to use a stimufield cap to address hair loss. They aim to avoid finasteride and minoxidil while hoping to stop hair loss and regrow hair.

User visited derma doctor, suggested finasteride, minoxidil, multivitamins, and PRP therapy. Another user advised against PRP due to cost and ineffectiveness.

Someone's brother tried Platelet-rich plasma (PRP) for hair loss; it had minimal effect on hair but improved skin appearance. Microneedling at home was suggested as a more sustainable alternative.

A topical serum made from monounsaturated fatty acids showed rapid hair growth in mice within 20 days, but it remains experimental for humans. Users humorously discussed the frequent success of hair growth treatments in mice and expressed skepticism about translating these results to humans.

Clascoterone 5% solution is not yet commercially available, with only the 1% solution currently sold for acne. Users discuss the potential of Clascoterone as a hair loss treatment, comparing it to other anti-androgens like RU58841 and Eucapil.

Pelage received $120 million for phase 3 of PP405, a potential hair loss treatment, but there is skepticism about its success. Some users believe any improvement over finasteride is a win, while others expect full hair regrowth.

Dr. Muñoz's discovery suggests that targeting potassium channels in fibroblasts could reactivate hair growth, offering new treatment possibilities for alopecia. Potential strategies include using minoxidil, diazoxide, and other potassium channel openers, as well as bioelectric devices and direct growth factor applications.

The conversation is about using coenzyme Q10 for hair loss alongside dutasteride. The effectiveness of coenzyme Q10 for treating androgenetic alopecia is questioned due to a lack of evidence.

A new topical medication, Clascoterone, shows promise for hair loss, improving hair count significantly. Trials for Breezula are ending, but sign-ups for PP405 trials are available for 2026.

The conversation discusses the ineffectiveness of dutasteride in halting hair loss for the user and explores the potential of PP405, which works through a different mechanism. Suggestions include considering a biopsy to determine the cause of hair loss and exploring other treatments like RU58841.

The conversation discusses using propanediol as an alternative to glycerin in PG-free minoxidil for better absorption. The user also plans to try nanoxidil, which may absorb more easily due to its smaller molecule size.

A user is considering microneedling to enhance absorption of a prescribed topical hair loss treatment containing Minoxidil, Dutasteride, and Latanoprost, while already taking oral Minoxidil and Dutasteride. They seek advice on the effectiveness and safety of combining these treatments, especially due to the cost and their desire to maximize results.

Copper peptides, specifically GHK-Cu, are being considered for hair regrowth, though skepticism exists due to questionable product sources. Users suggest finding reputable sources for potential benefits, while acknowledging traditional treatments like Minoxidil and Finasteride.

The user has been using finasteride, minoxidil, and needling for 11 months with limited progress and plans to add sulforaphane for 3 months. Another user suggested trying Procyanidin B2 for better results.

The conversation is about creating a higher concentration of the newly FDA-approved hair loss treatment, Clascoterone (Winlevi), through compounding pharmacies and possibly organizing group purchases. Some users are unfamiliar with Winlevi and are asking for an explanation of the drug.

Setipiprant trial for hair loss failed, showing no difference between placebo and treatment. Discussion also noted placebo users reporting side effects.

GHK-Cu peptide injections are discussed for hair growth, but users report mixed results and suggest focusing on DHT management first. Some users combine GHK-Cu with treatments like Minoxidil and Dutasteride, but emphasize its benefits for skin rather than hair.

The conversation is about the potential effectiveness of a hair loss treatment called pyrilutamide. One person has been using it since September and reports positive results.

Tretinoin can make minoxidil more effective for hair loss treatment, but some users did not see improved hair density with this combination and had better results with dutasteride.

PP405 is a new hair loss treatment advancing quickly in trials, generating excitement and skepticism about its effectiveness and marketing claims. Some see it as a potential alternative to minoxidil and finasteride, but concerns about long-term effects and the need for DHT blockers persist.

Clascoterone has shown promising results in increasing hair density without systemic side effects, potentially offering benefits similar to finasteride. There is skepticism due to the lack of published photos despite the market interest.

The conversation discusses hair loss treatments, specifically Setipiprant, finasteride, and bimatoprost. Setipiprant is suggested for maintenance, while bimatoprost is for regrowth, and combining them with dermarolling is recommended for better results.

The conversation discusses using latanoprost for hair loss treatment. Participants also mention Minoxidil, finasteride, and RU58841 as other treatments.

Pyrilutamide's effect on sebum production and scalp inflammation is unclear, with users noting no significant changes. Isotretinoin is mentioned as effective for reducing sebum, while Dutasteride and various shampoos have limited impact on oiliness and seborrheic dermatitis.

Ell-Cranell and Eucapil are discussed as hair loss treatments, with Ell-Cranell being a weak estrogen and DHT inhibitor that may reduce hair loss without systemic side effects. Alfatradiol is the active ingredient in these products.

RU58841 was the only treatment that slowed hair loss and reduced irritation for a DUPA sufferer after trying finasteride, minoxidil, and dutasteride with no success. The user continues using 6mg oral minoxidil, 0.5mg dutasteride, and an 8% RU58841 solution.